PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2024Cancer Research

Abstract CT242: Phase 2b study of alloHSCT patients receiving RGI-2001, an NKT cell activator, demonstrates safety and protection from acute GVHD, correlating with increased NKT cell number in patient blood

View Full Paper
Ask AI
Bookmark
Share

Authors

JBJack D. BuiCLCalvin K. LeeCCChristine Caron

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bui et al. (2024) studied this question.

synapsesocial.com/papers/68e70461b6db64358767e98fhttps://doi.org/10.1158/1538-7445.am2024-ct242
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies2025 · 1 citations
  2. 2The promising feeder-free allogenic NK cell therapy: Clinical outcomes of GIC-102 monotherapy (GIC-102101) and synergistic potential with GI-101 (CD80-IgG4 Fc-IL2v) in advanced solid tumors and hematologic malignancies.2024 · 1 citations
  3. 3Preclinical feasibility analysis for Phase I study using adoptive iNKT cell transfer to prevent GVHD2025
  4. 4An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation2025
  5. 5Abstract CT160: A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial)2024 · 4 citations